Exchange & Returns Information
Review Details
(0)
| Generic For | INTRON A |
|---|---|
| Active Ingredient | INTERFERON ALFA |
| Strength | 2B-3MIU |
| Manufacturer | INTAS PHARMACEUTICALS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 16.50 | $ 16.50 |
$ 14.03
Apply ZARVY26 (-15%)
You save $ 2.48
|
||
| 2 BOXES - 2 VIALS | $ 15.70 |
5% $ 33.00
$ 31.40
|
$ 26.69
Apply ZARVY26 (-15%)
You save $ 4.71
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 14.90 |
10% $ 49.50
$ 44.70
|
$ 38.00
Apply ZARVY26 (-15%)
You save $ 6.71
|
Reference information will be available soon.
Intalfa 3 MIU Injection contains Interferon Alfa-2B, a recombinant cytokine with broad immunomodulatory, antiviral, and antiproliferative properties. It is administered via injection for various cancers and viral infections. Interferon Alfa-2B enhances the immune response against abnormal or infected cells by stimulating cytotoxic T-cell activity, inhibiting viral replication, and regulating oncogene expression.
AntiCancer Drugs > Skin Cancer (Malignant Melanoma)
Used as adjuvant therapy after surgery in high-risk melanoma patients to prevent recurrence. It modulates immune responses and slows disease progression through cytokine activation.
Blood Cancer (Hairy Cell Leukemia, Follicular Lymphoma)
Used as first-line or second-line treatment in Hairy Cell Leukemia, and post-chemotherapy maintenance in Follicular Lymphoma to enhance hematologic response and prolong remission.
Kidney Cancer (Renal Cell Carcinoma)
Interferon Alfa-2B may be employed in selected cases of advanced RCC to stimulate immune-mediated tumor suppression.
Others (Kaposi's Sarcoma, Conjunctival MALT Lymphoma, Angioblastoma)
Effective in AIDS-related Kaposi's Sarcoma and off-label applications such as conjunctival lymphomas and angioblastoma, based on immunostimulatory activity.
DISEASES/SYMPTOMS > Chronic Hepatitis B and C
Approved for adult and pediatric patients with chronic viral hepatitis. When combined with ribavirin, it significantly improves sustained virologic response (SVR), particularly in genotype 1.
Condylomata Acuminata (Genital Warts)
Given intralesionally, it promotes local antiviral immunity and lesion clearance.
Idiopathic Thrombocytopenic Purpura
Shown to increase platelet counts in children by enhancing T-cell function and suppressing autoantibody production.
Hairy Cell Leukemia: 2 million IU/m² SC or IM, 3 times/week for up to 6 months. Use SC if platelets <50,000/mm³.
Malignant Melanoma: Induction 20 million IU/m²/day IV, 5 days/week for 4 weeks; then maintenance 10 million IU/m² SC, 3 times/week for 48 weeks.
Follicular Lymphoma: 5 million IU SC, 3 times/week up to 18 months, after CHOP chemotherapy.
Kaposi's Sarcoma: 30 million IU/m² SC or IM, 3 times/week until response or progression (up to 16 weeks).
Hepatitis C (adults): 3 million IU SC or IM, 3 times/week, 24–48 weeks with ribavirin or up to 96 weeks alone.
Hepatitis B (adults): 5 million IU daily or 10 million IU 3 times/week, SC or IM for 16 weeks.
Genital Warts: 1 million IU intralesionally per wart (up to 5 lesions), 3 times/week for 3 weeks; may repeat after 12–16 weeks.
Pediatric Hepatitis C (≥3 yrs): 3 million IU/m² SC, 3 times/week; 48 weeks (genotype 1), 24 weeks (genotypes 2/3).
Pediatric Hepatitis B (≥1 yr): Start at 3 million IU/m² SC, increase to 6 million IU/m², 3 times/week for 16–24 weeks.
MALT Lymphoma: 1 million IU intralesionally, 3 times/week for 12 doses (off-label).
Angioblastoma (≥4 months): 3 million IU/m² SC daily (case report basis).
Idiopathic Thrombocytopenic Purpura (≥4 yrs): 3 million IU/m² SC, 3 times/week for 4–12 weeks.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
